Human IL-2 ELISA Kit
Product Specifications
- Catalogue N°
- 950.010.048 - 1 x 48 Discovery (pre-coated)
950.010.096 - 1 x 96 (pre-coated)
950.010.192 - 2 x 96 (pre-coated) - Assay Range
- 31.25 pg/ml - 1000 pg/ml
- Sensitivity
- 7 pg/ml
- Target species
- Human
- Specificity
- Recognizes both natural and recombinant human IL-2
- Incubation
- 1h45
- Sample Type
- Serum, Plasma, Cell culture supernatant
- Sample Size
- 100 µl
- Cross Reaction
- No cross reactivity with other human cytokines. Cross reactivity with simian IL-2.
- Kit Content
- Diaclone ELISA Kits include pre-coated strip plates, biotinylated secondary antibody, standards, controls (where applicable), buffers, streptavidin-HRP, TMB, stop reagents and a detailed procedure.
References
- Altokka-Uzun, G. et al., Cephalalgia, 2015: 333102415570762 - Pubmed link
- Azadbakht, L. et al., Diabetes Care,2007;30(4):967-73 - Pubmed link
- Blanco B. et al., J. Immunol., 2003 ; 171(2):1070-7 - Pubmed link
- Blanco, B. et al., Blood, 2006;107(9):3575-83 - Pubmed link
- Buenestado, A. et al., J Parenter Enteral Nutr.,2006;30(4):286-96 - Pubmed link
- Calabia-Linares, C. et al., J. Cell Sci.,2011; 124(5): 820-830 - Pubmed link
- Casati, C. et al., Cancer Res.,2003;63(15):4507-15 - Pubmed link
- Doniz-Padilla, L. et al., Eur. J. Endocrinol.,2011;165(1):129-136 - Pubmed link
- Eilertsen, G. O. et al.,Lupus,2011;20(6):607-613. - Pubmed link
- Ge, N. L. et al., World J Gastroenterol.,2003; 9(10): 2182-5 - Pubmed link
- Giaccone, G. et al., Clin Cancer Res., 2002; 8 (12): 3702-9 - Pubmed link
- Gritzapis, A. D. et al., Br J Cancer,2003; 88(8): 1292-300 - Pubmed link
- Guo, Z. et al., Biomed Rep.,2016;5(5): 567-573 - Pubmed link
- Hadley, E. A. et al.,Clin Exp Immunol.,2005; 140(1): 101-8 - Pubmed link
- Harwood, S.L. et al.,Oncoimmunology. 2017 Sep 27;7(1):e1377874. - Pubmed link
- Hohn, H. et al., Clin Exp Immunol.,2003; 131(1): 102-10 - Pubmed link
- Kapsogeorgou E.K. et al., J. Immunol., 2001; 166(5): 3107 - 3113 - Pubmed link
- Kashyap, B. et al., J Trop Pediatr., 2011:fmr093 - Pubmed link
- Kerr J. et al., J. Gen. Virol., 2001; 82(Pt 12): 3011-3019 - Pubmed link
- Liu, C. P. et al., J Leukoc Biol., 2007; 81: 1276 - 1286 - Pubmed link
- Llorente, L. et al., Arthritis Rheum.,2000;43(8):1790-800 - Pubmed link
- Martin-Cofreces, N. B. et al., J Immunol., 2006;176(7):4201-7 - Pubmed link
- Martin-Cofreces, N. B. et al., J. Cell Biol.,2008; 182(5): 951-962. - Pubmed link
- Merlo, A. et al., Infect Immun.,2001;69(10):6022-9 - Pubmed link
- Montcuquet, N. et al., Immunology,2008;125(3): 320-30. - Pubmed link
- Nagao, Y. et al., Malar J.,2008; 7: 113. - Pubmed link
- Owens, G.L. et al.,J Immunother. 2018 Apr;41(3):130-140 - Pubmed link
- Rai, G. et al.,Ann Lab Med., 2018 Mar;38(2):125-131 - Pubmed link
- Ralph, C.et al.,Clin. Cancer Res.,2010;16(5): 1662-1672 - Pubmed link
- Robles-Valero, J.et al., Blood,2010; 115(21): 4174-4184. - Pubmed link
- Rodriguez-Zapata, M. et al., Infect. Immun.,2010; 78:3272-3279 - Pubmed link
- Rybka, J. et al.,Clin Exp Med.,2015; 16(4): 493-502. - Pubmed link
- Saifullah, S. Khan, et al.,Chem Cent J.,2013;7:163 - Pubmed link
- Saverino D. et al., J. immunol., 2002; 168(1): 207 - 215 - Pubmed link
- Shaw, D. M. et al.,Br J Cancer,2007; 96(4): 567-74. - Pubmed link
- Sobjanek, M. et al., Postepy Dermatol Alergol.,2016; 33(4): 263-8. - Pubmed link
- Stebbing, J. et al., Ann Oncol.,2003;14(11):1660-6 - Pubmed link
- Stebbing, J. et al., Clin Exp Immunol.,2004; 138(2): 312-6. - Pubmed link
- Su,C-C et al., Cancer Res., 2004; 64(6): 2148 - 2152 - Pubmed link
- Sun, Z. et al.,Cent Eur J Immunol.,2014;39(2): 216-22 - Pubmed link
- Tang, Y. et al., Am J Trop Med Hyg.,2008; 79(2): 154-158. - Pubmed link
- Tiemessen M.M. et al., Int. Immunol., 2003; 15(12): 1495 - 1504 - Pubmed link
- Trznadel-Grodzka, E. et al., Postepy Hig Med Dosw (Online),2012; 66: 843-7 - Pubmed link
- Trznadel-Grodzka, E. et al., Postepy Hig Med Dosw (Online),2012; 66: 848-54 - Pubmed link
- Urso, K. et al., Blood, 2011; 118: 795 - 803 - Pubmed link
- van der Burg, S. H. et al., PNAS,2007; 104(29): 12087-12092. - Pubmed link
- Woerly G. et al., J. Exp. Med., 1999; 190(4):487-495 - Pubmed link
- Goyal, S. et al.,Ind Psychiatry J. 2017 Jul-Dec;26(2): 201-206. - Pubmed link
- Gyuleva, I. et al., Dose Response. 2018 Aug 15;16(3):1559325818785564 - Pubmed link
- Kashyap, B. et al., Indian J Clin Biochem. 2018 Jul;33(3):334-340. - Pubmed link
- Rai, G. et al., Microb Cell Fact. 2020; 19: 215. - Pubmed link
- Sharma, S. et al., Clin Drug Investig. 2020; 40(4): 327–334. - Pubmed link
- Colarusso, C. et al., Biomedicines. 2021 Dec; 9(12): 1931. - Pubmed link
- Mandrup, O.A. et al., Commun Biol. 2021; 4: 310. - Pubmed link
- Dosil, S.G. et al., eLife. 2022; 11: e76319. - Pubmed link
Related products
- 855.020.000 - Anti-Human IL-2 Azide Free
- 855.021.019 - Anti-Human IL-2 FITC Conjugated
- 855.022.019 - Anti-Human IL-2 PE Conjugated
- 850.870.048 - Human IL-2 High Sensitivity ELISA Kit
- 860.000.048 - Murine IL-2 ELISA Kit
- 851.500.001 - Human IL-2 ELISA Set
- 861.000.001 - Murine IL-2 ELISA Set
- 856.001.001 - Human IL-2 ELISpot Set
- 856.001.001PC - Human IL-2 ELISpot Kit
- 874.040.001 - Human IFN-γ / IL-2 Dual ELISpot Set
- 874.042.001 - Human IFN-γ / IL-2 Dual Fluorospot Set
- 874.050.001 - Human IL-10 / IL-2 Dual ELISpot Set
- 862.001.001 - Murine IL-2 ELISpot Set
- 862.001.001PC - Murine IL-2 ELISpot Kit
- 869.000.010 - Human IL-2 ELISpot Pair
- 870.010.010 - Murine IL-2 ELISpot Pair
- 874.052.001 - Human IL-10 / IL-2 Dual Fluorospot Set
- 670.100.096 - Rat IL-2 ELISA kit
- 715-H02-010-CF - Recombinant Human Interleukin-2 (IL-2)-CF
- 715-H02-010-BSA - Recombinant Human Interleukin-2 (IL-2)-BSA
BACKGROUND
IL-2 is a powerful immunoregulatory lymphokine produced by T-Cells in response to antigenic or mitogenic activation. IL-2 stimulates growth and differentiation of B-Cells, most T-cells, NK cells, monocytes and macrophages.
Mature IL-2 is a 15.4kDa globular glycoprotein containing 133 amino acid residues including one intrachain disulfide bond between residues 58 and 105.
Apart from its most important role to mediate antigen-specific T-lymphocyte proliferation, IL-2 modulates the expression of interferon-g and major histocompatibility antigens.
Alterations in the ability of T-cell to synthesize IL-2 have been observed in physiologic and pathologic states. Currently, IL-2 is used to enhance the immune system of patients for the treatment of cancer and infectious disease.
Version 26 - 09.22
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.